Current Cancer Drug Targets


Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204


Nerve Growth Factor Receptors and Signaling in Breast Cancer

Volume:4   Issue:6
Pp: 463-470
Laurent Dolle, Eric Adriaenssens, Ikram El Yazidi-Belkoura, Xuefen Le Bourhis, Victor Nurcombe and Hubert Hondermarck
DOI: 10.2174/1568009043332853

Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?

Volume:4   Issue:6
Pp: 471-482
E. Papadimitriou, A. Polykratis, M. Hatziapostolou, A. Parthymou, C. Polytarchou and C. Mikelis
DOI: 10.2174/1568009043332835

Two-Domain Vascular Disruptive Agents in Cancer Therapy

Volume:4   Issue:6
Pp: 501-509
Stanislaw Szala
DOI: 10.2174/1568009043332826

The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma

Volume:4   Issue:6
Pp: 511-520
Noriyuki Takai, Tami Ueda, Masakazu Nishida, Kaei Nasu and Isao Miyakawa
DOI: 10.2174/1568009043332871

Mammaglobin-Based Strategies for Treatment of Breast Cancer

Volume:4   Issue:6
Pp: 531-542
Peter S. Goedegebuure, Mark A. Watson, Carsten T. Viehl and Timothy P. Fleming
DOI: 10.2174/1568009043332862